Article

Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024

2025-07-18

Abstract excerpt

<title>Abstract</title> <p>Background Rybrevant (amivantamab), the first bispecific antibody targeting EGFR and MET, has been approved for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Our study employed FAERS database to examine cutaneous adverse events (AEs) associated with rybrevant. Methods Using data from the FAERS between Q2 2021 and Q4 2024, we conducted a comprehensive...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: af8a330e-a8cd-5669-acc3-bc504e27e0fc
DOI: 10.21203/rs.3.rs-7041785/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024DOI 10.21203/rs.3.rs-7041785/v1Read

Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA DatabaseSemantic proximity Read

A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting systemSemantic proximity Read

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.Semantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read

Adverse event profile differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: a real-world, pharmacovigilance studySemantic proximity Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read